| Ping Chen,Bei Zhang,Guifang Guo,Liangping Xia,Huijuan Qiu. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Oncol Transl Med, 2014, 13: 229-234. |
| 肝动脉灌注化疗联合全身化疗作为一线和非一线治疗不可切除肝转移患者的疗效对比 |
| Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases |
| |
| DOI： |
| 中文关键词: 结肠癌；不可切除性肝转移；全身化疗；肝动脉灌注化疗 |
| 英文关键词: colorectal cancer (CRC); unresectable hepatic metastasis; systemic chemotherapy (SYC); hepatic arterial chemotherapy (HAIC) |
| 基金项目:国家自然科学基金项目(No. 81302141)；广东省中医药管理局项目(No. 20111169)；广东省科技计划项目(No. 2010B031600317)；中山大学青年教师培训项目(No. 12ykpy56) |
| Author Name | Affiliation | | Ping Chen | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | Bei Zhang | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | Guifang Guo | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | Liangping Xia | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | Huijuan Qiu | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China |
|
| Hits: 11301 |
| Download times: 10696 |
| 中文摘要: |
| 目的：肝动脉灌注化疗（HAIC）联合全身化疗（SYC）对不可切除的结肠癌肝转移有潜在治疗价值。本篇回顾性研究基于单中心的临床经验，旨在研究这种联合治疗对中国不可切除性肝转移患者的疗效和安全性。方法：本研究中共纳入54名确诊不可切除肝转移的结肠癌患者，其中23名患者将HAIC联合SYC作为一线治疗（组1），另31名患者将HAIC联合SYC作为非一线治疗（组2）。两组的疗效差异分析采用SPSS 19.0统计软件。结果：组1和组2 的总反应率（ORR）分别为52.2%和25.8% (P=0.047)，疾病控制率（DCR）分别为65.2%和35.5% (P=0.031)。两组的中位无进展生存期（PFS）分别是6.8个月和3.3个月 (P=0.002)，中位肝无进展生存期(H-PFS)分别为8.8个月和3.7个月（P=0.001）。组1和组2的中位总生存期（OS）分别为18.8个月和13.7个月 (P=0.121)。两组均未见致死性毒性反应。3-4度中性粒细胞减少（9.7%）和口腔炎（6.5%）的毒性反应仅见于组2，3度高胆红素血症（4.3%）仅见于组1。组1和组2的3度胃肠道反应分别是8.7%和6.5%。
结论：HAIC联合SYC治疗不可切除性肝转移的结肠癌患者，具有积极的疗效和安全性。 |
| 英文摘要: |
| Objective: The combination of hepatic arterial chemotherapy (HAIC) and systemic chemotherapy (SYC) has potential effect on colorectal cancer (CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metastasis and received combined HAIC and SYC. Among the patients, 23 of them received HAIC plus SYC when they developed liver metastases as first-line treatment (Group 1), and 31 patients received HAIC plus SYC as non-first-line treatment (Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate (ORR) were 52.2% and 25.8% respectively in Groups 1 and 2 (P = 0.047), and the disease control rate (DCR) were 65.2% and 35.5% respectively in Groups 1 and 2 (P = 0.031). The median progression-free survival (PFS) were 6.8 and 3.3 months (P = 0.002), the median hepatic progression-free survival (H-PFS) were 8.8 and 3.7 months (P = 0.001), and the median overall survival (OS) were 18.8 and 13.7 months (P = 0.121) in Groups 1 and 2, respectively. No fatal reaction was observed and no significant difference of adverse reaction was found in two groups. Grade 3/4 toxic effects included neutropenia (9.7% in Group 2 only), gastrointestinal reaction (8.7% in Group 1 and 6.5% in Group 2), stomatitis (6.5% in Group 2 only) and hyperbilirubinemia (4.3% in Group 1 only). Conclusion: HAIC combined with SYC showed promising efficacy and safe profiles on CRC patients with unresectable liver metastases. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|